ASCO® 2024 Summary: "Gynecologic Oncology Updates"

2024 ASCO® Annual Meeting Insights Hub

R. Salani

ESMO 2024 Insights: Final OS With Niraparib as 1L Maintenance in Adv…

2024 ESMO Annual Meeting Insights Hub

B. Monk

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

ESMO 2024 Insights: Rucaparib +/- Nivo as Maintenance in Newly Diagn…

2024 ESMO Annual Meeting Insights Hub

B. Monk

ASCO® 2024 Summary: "Timing of Debulking Surgery in Advanced Endomet…

2024 ASCO® Annual Meeting Insights Hub

A. Karam

Gynecologic Oncology Updates: Expert Perspective on Key Trial Findin…

Yale Cancer Center

E. Ratner

ESMO 2024 Insights: PRIMA Trial - Newly Diagnosed Advanced Ovarian C…

ecancer

A. González-Martín

Cancer Screening Molecular Tools

Fengting Yan

ESMO 2024 Insights: Mirvetuximab Soravtansine-gynx (MIRV) in Platinu…

2024 ESMO Annual Meeting Insights Hub

A. Secord

2024 Updates in Ovarian Cancer

Total Health

T. Tillmanns

Updates on Maintenance Therapy in Advanced Ovarian Cancer

Paul DiSilvestro

Antibody Drug Conjugates in Gynecologic Oncology: From Bench to Beds…

UCLA Health

G. Konecny

Ovarian Cancer Patient Experience With Niraparib: Assessing QoL Data…

Erin Crane

Treatment Options for Platinum-Sensitive Recurrent Ovarian Cancer

Richard Penson

ESMO 2024 Summary: Antibody Drug Conjugates (ADCs) - Identifying New…

2024 ESMO Annual Meeting Insights Hub

S. Banerjee

ASCO® 2024 Insights: "BrUOG 354 Trial Final Results - Nivo vs. Nivo/…

2024 ASCO® Annual Meeting Insights Hub

D. Dizon

Novel Approaches in Oncology: Early Interception & BRCA Advances in …

Houston Methodist

P. Munster

ESMO 2024 Insights: HER2 Expression and Its Relationship to HRD Stat…

2024 ESMO Annual Meeting Insights Hub

D. Lee

ASCO® 2024 Summary: "Unveiling the Unique Identity of Clear-Cell End…

2024 ASCO® Annual Meeting Insights Hub

F. Blanc-Durand